German biomarker company seragy has raised approximately $13.4 million to scale its SeRAS platform, which quantifies and subtypes misfolded protein aggregates underlying Alzheimer's, Parkinson's and ALS. Where existing seed amplification assays return a binary positive or negative result, SeRAS aims to produce a reproducible molecular fingerprint describing aggregate behavior and disease subtype. The shift from detection to characterization has direct implications for patient stratification and drug development in neurodegeneration.
Key Points
- Seragy secured €12m in mixed debt, equity and public funding
- SeRAS platform quantifies and subtypes protein aggregates beyond binary detection
- Michael J. Fox Foundation grant supports quantitative Parkinson's assay development
Longevity Analysis
Protein aggregation is one of the clearest markers of failing cellular maintenance, and the capacity to clear or refold damaged proteins declines steadily with age. Measuring not merely whether aggregates are present but how they behave converts a yes-or-no signal into something interpretable — the difference between knowing a problem exists and knowing which problem it is. For neurodegeneration, where pathology accumulates silently for decades before symptoms appear, quantitative subtyping is the precondition for intervening while regenerative capacity remains intact.
Original published by Longevity.Technology, by Kyle Umipig.